KRYSTAL BIOTECH INC.

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

27 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

09 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

06 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

30 Oct 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

28 Sep 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

21 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

07 Sep 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million

21 Aug 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights

07 Aug 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

26 Jul 2023 13:14:18 By Nasdaq GlobeNewswire

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis

03 Jul 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Upcoming Investor Conferences

05 Jun 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces $160 Million Private Placement Equity Financing

22 May 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

19 May 2023 10:57:02 By Nasdaq GlobeNewswire

Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

08 May 2023 05:23:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program

24 Apr 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting

13 Apr 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

06 Mar 2023 04:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

02 Mar 2023 04:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

27 Feb 2023 04:00:00 By Nasdaq GlobeNewswire